XENON PHARMACEUTICALS INC (XENE) Stock Balance Sheet
NASDAQ:XENE - Nasdaq - CA98420N1050 - Common Stock - Currency: USD
| MRQ (2024-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 136.73M | 142.71M | 148.64M | 57.20M | 175.70M | |||
| Marketable Securities | 584.80M | 484.19M | 489.44M | 534.80M | 376.10M | |||
| Receivables | 853.00K | 1.47M | 874.00K | 1.00M | 2.80M | |||
| Other Current Assets | 5.70M | 6.89M | 6.01M | 7.20M | 4.50M | |||
| Total Current Assets | 728.09M | 635.26M | 644.96M | 600.30M | 559.00M | |||
| Non-Current Assets | ||||||||
| PPE Net | 18.71M | 18.22M | 18.85M | 16.90M | 12.50M | |||
| Investments And Advances | 129.06M | 127.50M | 292.79M | 128.70M | N/A | |||
| Other Non-Current Assets | 8.15M | 17.16M | 8.20M | 8.30M | 500.00K | |||
| Total Non-Current Assets | 155.92M | 162.88M | 319.84M | 153.80M | 13.00M | |||
| TOTAL ASSETS | 884.01M | 798.14M | 964.80M | 754.10M | 572.00M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 21.79M | 30.52M | 18.68M | 13.90M | 10.40M | |||
| Accounts Payable | 10.60M | 5.07M | 8.95M | 8.80M | 3.90M | |||
| Other Current Liabilities | N/A | N/A | N/A | N/A | 0.00 | |||
| Total Current Liabilities | 31.29M | 35.59M | 27.27M | 22.70M | 14.30M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 8.68M | 7.65M | 9.60M | 9.90M | 7.70M | |||
| Total Non-Current Liabilities | 8.68M | 7.65M | 9.60M | 9.90M | 7.70M | |||
| TOTAL LIABILITIES | 39.96M | 43.24M | 36.88M | 32.60M | 22.00M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -771.00M | -899.47M | -665.14M | -482.70M | -357.40M | |||
| Additional Paid In Capital | 176.80M | 199.15M | 156.76M | 142.10M | 117.50M | |||
| Common Shares | 1.44B | 1.46B | 1.44B | 1.07B | 790.90M | |||
| Other Shareholders' Equity | -2.21M | -1.61M | -77.00K | -3.00M | -1.00M | |||
| Shares Outstanding | 75.67M | 76.42M | 75.37M | 62.60M | 51.60M | |||
| Tangible Book Value per Share | 11.15 | 9.88 | 12.31 | 11.53 | 10.51 | |||
| Total Shareholders' Equity | 844.05M | 754.90M | 927.92M | 721.50M | 550.00M | |||
| TOTAL LIABILITIES AND EQUITY | 884.01M | 798.14M | 964.80M | 754.10M | 572.00M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 23.27 | 17.85 | 23.65 | 26.44 | 39.09 | |||
| Return On Assets (ROA) | -22.52% | -29.36% | -18.90% | -16.57% | -13.48% | |||
| Return On Equity (ROE) | -23.58% | -31.04% | -19.66% | -17.32% | -14.02% | |||
All data in USD , ROIC based on taxRate of 0.21